secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001764013-24-000147
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant reports Q1 FY2025 net loss $87.2M; completes batoclimab MG enrollment
--------------------------------------------------------------------------------

- Net loss $87.2M ($0.60/share) vs $73.9M ($0.57) YoY; cash $560M as of June 30, 2024.
- R&D expenses $75.5M, up 49% YoY, driven by IMVT-1402 prep and batoclimab trials.
- Completed enrollment in batoclimab pivotal MG trial; top-line results expected by March 31, 2025.
- Plans to initiate 4-5 potentially registrational programs for IMVT-1402 by March 31, 2025; 3 IND applications active by end-2024.
- Graves' disease program update expected fall 2024; batoclimab TED top-line data in H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401324000147/0001764013-24-000147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401324000147/imvt-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001764013-24-000147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer